Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.

Completed

• Conditions: Coagulation Disorder

• Registration Number: NCT04479280
• Lead Sponsor: Assiut University

Brief Summary

Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world .

Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-19
• Study First Submitted QC: 2020-07-19
• Study Start: 2020-07-20
• Study First Posted: 2020-07-21
• Primary Completion: 2020-08-16
• Study Completion: 2020-08-16
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-07
• Last Update Posted: 2020-09-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• COVID 19 critically ill patients

Exclusion Criteria

• any critical illness not related to COVID 19

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
clot rate formation	30 minutes	measuring how rapid the sample will get clotted

Trial Locations

Locations (1)

Assiut university; 🇪🇬 Assiut, Egypt